(前台大心臟外科主任:王水深)輔大醫院一定要做: 急症/重症/難症 !

輔大醫院靠兩大祕密武器突圍 30位台大名醫帶槍投靠 發展高端貴賓級服務醫院最重要的就是醫療團隊夠強，才能開拓出自己的藍海，輔大要用什麼來比拚？ 除了社區醫療，輔大醫院將發展高端貴賓級服務，希望透過捐款回饋整個醫療體系。2017/06/01 出處：財訊雙週刊 第 530 期 作者：段詩潔 我的命，有一半是上帝給的，一半是把我救起來的心臟科醫生給的。兩年前已經黑掉的人，現在可以持續演奏鋼琴；希望新莊、五股、泰山地區很多人，也有機會跟我一樣重生。」2014年5月，輔仁大學附設醫院剛開始動工的同時，一手推動計畫的輔大校長江漢聲，卻因心肌梗塞，一度倒下。經過緊急搶救後清醒，他更體認到輔大醫院成立的迫切性。「蓋醫院，第一個應該問，這個地方需要嗎？」以新北市泰山地區為例，最近的醫院在林口、淡水，但若是遇到心肌梗塞這種必須分秒必爭，「到我們醫院的，絕對不會送走。」尤其有心臟內科權威江福田、心臟外科權威王水深坐鎮，擁有全台最先進的複合手術室，「急症、重症、難症就是輔大醫院一定要做的。」

募款職業級琴藝也上場 找人成功最重要關鍵 蓋醫院是大工程，需要大資金，面對諸多質疑與反對，○七年取得天主教會樞機主教單國璽及董事會同意後，江漢聲最重要的課題就是「找錢」。10年來，為了募款，江漢聲見過無數的人、吃過無數次飯局、開過無數次會議，也彈過無數首動人的曲子，飛航里程更是不斷累積中。醫學院院長林肇堂就開玩笑說，「校長多彈一首曲子，募款多一個零。」「找錢」的同時，也得「找人」。輔大醫院吸引30幾位台大名醫帶槍投靠，號稱空前的卡司陣容，成了一大賣點。江漢聲口中「醫術好、人格特質好」的王水深，就是即將揭牌的輔大醫院院長；曾擔任台大醫院心臟外科主任的王水深，經常與閻羅王拔河，參與的心臟移植手術超過550例。江漢聲認為，對於很多財團法人醫院來說，醫師只是高級員工；輔大醫院給的是讓醫師自由自在發揮的空間。為醫院網羅不少好醫師的林肇堂，更以「開墾大西部」來形容說，每一家醫院都有自己的系統，但是輔大醫院沒有包袱，「有無限的想像空間，讓你來表演。」林肇堂直言，能吸引人才到輔大醫院的關鍵，除了待遇要好，另一個誘因就是提供教職。「這是『我們的』醫院，不是我找你來，而是你想找誰來，這個科要怎麼做？我們一起去規畫，目標一致，有錢賺就分給你；當醫院能賺錢，錢就能回到醫學院的教學上。」江漢聲說，醫學院本身提供很多教職，教育學生則要靠醫院幫忙；醫學院是很窮的，將來要靠醫院來養醫學院，而醫學院仍要主導醫院。輔大醫院要如何脫穎而出？醫院籌備處主任陳俊賢表示，輔大醫院重視整合性，病人看診不需要東奔西跑，是真正「以病人為中心的醫療」；輔大也以資訊科技發展為目標，建構有未來性的智慧型醫院。王水深舉例，像輔大家醫科就是要服務到家，做好社區服務；像一般女性感覺胸部有異樣，不必煩惱掛什麼科，只要到婦女中心報到就可以了。」

浩鼎 擴大研發主力 收購臨床前小分子新藥 (TH-3424/ OBI-3424: Threshold Pharmaceuticals)/ Ascenta Pharmaceuticals合作pre-IND動物毒理測試

浩鼎 發言日期106/06/01 發言時間 發言人黃秀美 發言人職稱總經理 發言人電話(02)2786-6589 主旨 說明本公司宣布收購首創抗癌新藥OBI-3424 將開發為治療AKR1C3酵素高度表現癌症之潛力療法 符合條款 第51款 事實發生日106/06/01 說明1.事實發生日:106/06/01 2.公司名稱:台灣浩鼎生技股份有限公司 3.與公司關係(請輸入本公司或子公司):不適用 4.相互持股比例:不適用 5.傳播媒體名稱:中時電子報 6.報導內容:浩鼎生技 (4174)宣布與美國加州Threshold Pharmaceuticals 簽訂合約，取得小分子首創新藥 (first-in-class) TH-3424全球智財權和專利權（但不包括中國、香港、澳門、台灣、日、韓、新加坡、馬來西亞、泰國、土耳其及印度），並重新命名OBI-3424，將開發為治療AKR1C3酵素高度表現癌症之潛力療法，成為浩鼎產品線的新生力軍...。 7.發生緣由:本公司今日宣布與美國加州Threshold Pharmaceuticals 簽訂合約，收購小分子首創新藥 (first-in-class) TH-3424，並重新命名OBI-3424，成為浩鼎產品線的新生力軍。OBI-3424為一化療前驅型新藥，它會選擇性地在AKR1C3酵素作用下，釋出強效DNA烷基化劑；這種選擇性的啟動機制﹐OBI-3424與傳統烷基化藥物，如cyclophosphamide 與ifosfamide有很大區別。根據文獻，AKR1C3在多種抗藥性及難治癌症的腫瘤細胞中均有過度表現，舉例來說，大多數肝細胞癌病人即有AKR1C3高度表現。OBI-3424在臨床前動物試驗中﹐展現了高度抗癌活性，並且對肝細胞癌標準治療藥物sorafenib有抗藥性的動物也有效果。AKR1C3的表現量會在接受去勢療法後上升，因此去勢抗性攝護腺癌亦為OBI-3424的開發方向。另外，美國國家癌症研究院 (National Cancer Institute)也正進行臨床前試驗，研究OBI-3424用於治療T細胞急性淋巴性白血病的效果。此產品另一個特色是，可用免疫染色法測量AKR1C3表現量；亦即試驗將可選擇AKR1C3高度表現的病人，以辨識出最可能對OBI-3424藥物治療產生良好抗癌反應的病人，有利於依此制定相對精準的臨床發展有效策略。根據雙方合約，Threshold將移轉OBI-3424所有權，以及臨床前及製造相關數據予浩鼎；浩鼎將支付Threshold一次性款項，未來則不需另行支付Threshold任何款項或權利金。這項轉讓除了亞洲區部份國家(見註一)外，浩鼎將取得OBI-3424的全球智慧財產及其商務、開發與生產權利。註一: 浩鼎取得全球智財權和專利權，但不包括下列國家/地區:中國、香港、澳門、台灣、日本、韓國、新加坡、馬來西亞、泰國、土耳其及印度。 8.因應措施:無 9.其他應敘明事項:無

浩鼎宣布收購首創抗癌新藥OBI-3424  2017年06月01日彭暄貽 浩鼎生技 (4174)宣布與美國加州Threshold Pharmaceuticals簽訂合約，取得小分子首創新藥 (first-in-class) TH-3424全球智財權和專利權（但不包括中國、香港、澳門、台灣、日、韓、新加坡、馬來西亞、泰國、土耳其及印度），並重新命名OBI-3424，將開發為治療AKR1C3酵素高度表現癌症之潛力療法，成為浩鼎產品線的新生力軍。浩鼎總經理黃秀美表示，將持續臨床前開發﹐並希望發展OBI-3424為表現AKR1C3癌症的優秀治療方案。這個首創新藥強化了浩鼎產品線﹐也引領浩鼎朝世界級癌症生技公司目標更邁進一步。目前規劃加速OBI-3424開發腳步，將在2018年初向美國食品藥物管理局(FDA)提出臨床試驗申請(IND)。浩鼎指出，OBI-3424為一化療前驅型新藥﹐它會選擇性地在AKR1C3酵素作用下﹐釋出強效DNA烷基化劑；這種選擇性的啟動機制﹐OBI-3424與傳統烷基化藥物，如cyclophosphamide 與ifosfamide有很大區別。據雙方合約，Threshold將移轉OBI-3424所有權。及臨床前及製造相關數據予浩鼎；浩鼎將支付Threshold一次性款項，未來則不需另行支付Threshold任何款項或權利金。這項轉讓除了亞洲區部份國家(見註一)外，浩鼎將取得OBI-3424的全球智慧財產及其商務、開發與生產權利。根據文獻，AKR1C3在多種抗藥性及難治癌症的腫瘤細胞中均有過度表現，舉例來說﹐大多數肝細胞癌病人即有AKR1C3高度表現。OBI-3424在臨床前動物試驗中﹐展現高度抗癌活性﹐並且對肝細胞癌標準治療藥物sorafenib有抗藥性的動物也有效果。在去勢動物中﹐AKR1C3的表現量會提升﹐因此去勢抗性攝護腺癌亦為OBI-3424的開發方向。另美國國家癌症研究院 (National Cancer Institute)也正進行臨床前試驗﹐研究OBI-3424用於治療T細胞急性淋巴性白血病的效果。此產品另一個特色是可用免疫染色法測量AKR1C3表現量；亦即試驗將可選擇AKR1C3高度表現的病人﹐以辨識出最可能對OBI-3424藥物治療產生良好抗癌反應的病人，有利於依此制定相對精準的臨床發展有效策略。(工商)

THRESHOLD IS EVALUATING TH-3424, FOR TUMORS THAT OVEREXPRESS AN ENZYME, AKR1C3, THAT MAKES THEM RESISTANT TO RADIATION THERAPY AND CHEMOTHERAPY.  TH-3424 is a novel small-molecule that targets cancers that overexpress high levels of the enzyme aldo-keto reductase 1C3 (AKR1C3). Tumors overexpressing AKR1C3 can be resistant to radiation therapy and chemotherapy. TH-3424 is a prodrug that selectively releases a potent DNA cross-linking agent in the presence of AKR1C3.  TH-3424 is being evaluated for the potential treatment of hepatocellular (liver) cancer (HCC), castration-resistant prostate cancer (CRPC), T-cell acute lymphoblastic leukemias (T-ALL), and other cancers expressing high levels of aldo-keto reductase family 1 member C3 (AKR1C3). Preliminary nonclinical toxicology studies suggested an adequate therapeutic index that the Company believes warrants continued development. The Company is conducting Investigational New Drug (IND)-enabling toxicology studies of TH-3424 in collaboration with Ascenta Pharmaceuticals, Ltd.    

HAROLD E. "BARRY" SELICK, PH.D. CHIEF EXECUTIVE OFFICER  Harold E. "Barry" Selick, Ph.D. joined Threshold as Chief Executive Officer in June 2002. Between June 2002 and July 2007, Dr. Selick was a Venture Partner of Sofinnova Ventures, Inc., a venture capital firm. From January 1999 to April 2002, he was Chief Executive Officer of Camitro Corporation, a biotechnology company. From 1992 to 1999, he was at Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome plc, most recently as Vice President of Research. Prior to working at Affymax he held scientific positions at Protein Design Labs, Inc. and Anergen, Inc. As a staff scientist at Protein Design Labs, he co-invented the technology underlying the creation of fully humanized antibody therapeutics and applied that to PDL's first product, Zenapax, which was developed and commercialized by Roche for treating kidney transplant rejection. Dr. Selick received his B.S. and Ph.D. from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco. 

TILLMAN PEARCE, M.D. CHIEF MEDICAL OFFICER  Tillman Pearce, M.D. joined Threshold as Chief Medical Officer in February 2012. From April 2007 until March 2011, Dr. Pearce served as Chief Medical Officer at KaloBios Pharmaceuticals, Inc. Dr. Pearce has approximately 15 years of experience in the biopharmaceutical industry in both Europe and the United States. Prior to joining KaloBios, he was at Protein Design Labs in Paris, France, where he held the position Senior Director, Clinical Research and directed their European office. Between 1997 and 2002, Dr. Pearce was Medical Director at Sanofi-Synthelabo, S.A. in Paris, France, in their Oncology Business Unit. Prior to that, he held the position of Director, Clinical Research at Novartis Pharma AG in Basle, Switzerland. Dr. Pearce received his M.D. from the Medical College of Georgia and is board-certified in both internal medicine and hematology. 

JOEL A. FERNANDES, C.P.A SENIOR VICE PRESIDENT, FINANCE AND CONTROLLER  Joel Fernandes was appointed Threshold's Senior Vice President, Finance and Controller in March 2016. Previously, he served as Threshold's Vice President, Finance and Controller since May 2011 having held roles of increasing responsibility in finance and accounting since joining the company in 2006. Prior to joining Threshold, Mr. Fernandes served as Associate Director of Finance at Theravance Inc., Senior Manager of Corporate Finance at KLA-Tencor, and Assistant Controller of ALZA Corporation. Mr. Fernandes holds a CPA and a Masters in Accountancy from Manchester College, Indiana. 

CHARLES P. HART, PH.D. SENIOR VICE PRESIDENT, BIOLOGY  Charles Hart, Ph.D., was appointed Threshold's Vice President, Biology in 2008. He joined the company as Senior Director, Biology in 2004. Dr. Hart is responsible for in vitro and in vivo preclinical translational studies. Prior to joining Threshold, Dr. Hart was Senior Director, Biology at Galileo Pharmaceuticals, Director of Drug Discovery at Signature Bioscience, and a Research Unit Director at Affymax (a Glaxo company). Dr. Hart holds an A.B. from UC Berkeley, an M.S. from Stanford University, and a Ph.D. in Molecular Biology and Genetics from Yale University. Dr. Hart completed a postdoctoral fellowship at the University of Strasbourg, France. 

ERIC D. MALEK, M.B.A. SENIOR VICE PRESIDENT, CORPORATE DEVELOPMENT  Eric Malek was appointed Threshold's Senior Vice President, Corporate Development in March 2016. Mr. Malek joined Threshold as Vice President, Corporate Development in 2010 and led negotiations for the TH-302 co-development and co-commercialization partnership with Merck KGaA. Prior to joining Threshold, he led corporate development at BiPar Sciences where he initiated the partnering effort that led to BiPar's acquisition by Sanofi-Aventis. Prior to BiPar, Mr. Malek was Vice President, Corporate Development at Allos Therapeutics, where he led the acquisition and product planning efforts for FOLOTYN®, indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Before Allos, Mr. Malek held business development positions at Gilead Sciences, NeXstar Pharmaceuticals, Ilex Oncology and Research Corporation Technologies as well as research positions at Janssen Pharmaceuticals. Mr. Malek holds a B.A. in Biochemistry from the University of Arizona and an M.B.A. from the University of Michigan. 

MARK HOPKINS, J.D., PH.D. VICE PRESIDENT OF INTELLECTUAL PROPERTY AND ASSISTANT GENERAL COUNSEL  Mark Hopkins, J.D., Ph.D., joined Threshold as Vice President of Intellectual Property and Assistant General Counsel in July 2015. Dr. Hopkins is responsible for advising the company on a variety of legal issues both domestically and internationally. Dr. Hopkins has more than 16 years of legal experience in the pharmaceutical industry. Prior to joining Threshold, Dr. Hopkins was a partner at Kilpatrick Townsend and Stockton LLP where he led a team of legal professionals providing legal opinions and securing patents for pharmaceutical companies on their key drugs. Dr. Hopkins began his career as a senior scientist and patent agent with the Dow Chemical Company, where he led a multidisciplinary team responsible for lead generation in several novel chemical applications. Dr. Hopkins was an American Cancer Society postdoctoral fellow at Northwestern University, has a J.D. from the John Marshall Law School, a Ph.D. in Chemistry from the University of California, Irvine, and is the author of multiple legal and scientific publications.

KRISTEN QUIGLEY, B.A. VICE PRESIDENT OF CLINICAL OPERATIONS  Kristen Quigley was appointed Vice President of Clinical Operations in October 2016. Ms. Quigley has over 20 years of experience in the pharmaceutical/CRO industry in both Europe and the United States. She joined Threshold in June 2014 as Senior Director of Clinical Operations, leading cross-functional process-improvement initiatives and several successful CRO collaborations on the TH-302 program. Prior to joining Threshold, Ms. Quigley held various Project Management and Clinical Trial Management roles during a 12-year tenure with ICON Clinical Research, the most recent of which was Project Management Senior Director in ICON's Oncology and Hematology Division From 2013-2014. Between 2010-2011, Ms. Quigley was stationed in Stockholm, Sweden as co-Director of ICON's Nordic region. Prior to joining ICON, she held Project Management and Clinical Research Associate roles during a 5-year tenure at Kendle International. Kristen received her B.A. from Washington University in St. Louis. 

工研院 開發 智慧衣&定位鞋墊!

工研院智能系統主題館 展示智慧生技研發能量 2017-06-01 19:08經濟日報 記者　江碩涵╱即時報導 工研院產經中心（IEK）預估，全球精準醫療（Precision Medicine）市場在2015至2020年的年複合成長率約12.3%，市場規模也將從2015年389億美元成長至2020年695億美元，顯示誰能透過更快速、精確的診斷，替患者提供適切治療，就能站到市場浪頭上。經濟部技術處支持下，工研院在2017台北國際電腦展（COMPUTEX TAIPEI 2017）的「智能系統主題館」中展示「健康樂活姿勢追蹤系統」，可結合衣服穿在身上，隨時偵測分析姿勢，工研院另外展出9項「智慧生技」創新技術，可透過情境式互動體驗實際感受。「健康樂活姿勢追蹤系統」是一個智慧姿勢追蹤系統平台，可結合紡織品隱藏於穿著中成為智慧產品，可分析人體姿勢，提醒不良姿勢或運動等可能受傷行為；「iSmartweaR智慧感知衣」則運用奈秒脈衝近場感測與耐水洗導電膠技術，改善傳統智慧衣不耐水洗且須緊貼皮膚偵測生理訊號的困擾，運動監測與健康照護提供更方便的選擇。對照護者而言，即時確認被照護者位置至關重要。工研院結合壓電能源採集、GPS定位與自有無線異質平台itri-patch開發出的「獵能定位鞋墊」，可傳送穿戴者位置至雲端，並延長產品使用時間。同樣結合獵能技術的「無電池環境感測便利貼」，則利用光能源蒐集取代電池，偵測週遭的溫度、濕度與一氧化碳，以確保環境舒適。工研院開發「手持式智慧型分子快速檢測系統」，30分鐘內可檢測病毒或細菌感染疾病，並可應用在基因變異與農漁牧、基改食品檢測；「膚齡檢測儀」則可協助檢測你的膚況、口腔與眼睛疾病。工研院另與馬偕醫院醫療團隊共同開發「積層製造（3D列印）服務平台」（AM as a service），整合工研院掃瞄、3D modeling、結構及製程分析技術，開發客製化3D列印的媽媽手輔護具，取代傳統包覆固定方式，不僅貼身，孔洞結構輕量化設計，讓固定手部不再悶不透氣並兼具美觀效果。

工研院南向拚 政績：簽署MOU (泰國國家科學院)

新南向政策台泰合作 工研院與泰國科學院簽約 2017-06-01 17:21聯合報 記者陳妍霖╱即時報導 泰國最近推動大規模經濟改革計畫「泰國4.0」，以數位、生技與創新為主軸，更投資1.5萬億泰銖推動東部經濟走廊建設，希望成為東盟最先進的經濟發展中心，看準合作契機，也配合新南向政策，工研院今日和泰國國家科學院共同簽署合作備忘錄，結合雙方優勢，打造台泰創新經濟產業價值鏈。工研院和泰國國家科學研究院分屬台灣及泰國兩個最重要的科技研發機構，其中泰國推動最重要政策是投資1.5萬億泰銖推動東部經濟走廊，也是泰國商品進入緬甸、柬埔寨等的重要中心。工研院董事長吳政忠認為，泰國推動的政策對台商，特別是中小企業目前規劃進行的供應鏈整合以及泰國、緬甸、柬埔寨等市場進入有很大契機，也是政府新南向政策創造互利共贏的新合作模式的區域鏈結、經貿合作、人才交流與資源共享的最佳選擇。

林榮錦 打造台灣生技工業銀行：晟德藥業集團 (益安/順天/永昕/金樺/澳優)

生技教父投資有一套澳優乳業3年獲利翻4倍 2017/06/01 17:52【鏡週刊報導】晟德藥業集團（4123）投資澳優乳業3年，有生技教父之稱的董事長林榮錦今表示，澳優乳業2016年度獲利較2015年翻漲超過4倍。為滿足大陸急速成長的嬰幼兒配方奶粉需求，澳優乳業今年5月已簽訂合約收購澳洲ADP工廠，在荷蘭斥資1.10億歐元打造的綠色工廠也將在今年第3啟用，全廠區落成後預計年產能達9萬噸，今年營收可望年增5成，獲利增4至5倍，大幅挹注晟德集團業績。晟德藥業集團是台灣最大的兒童水劑藥廠，投資範圍包含新藥開發、蛋白質與抗體藥物開發公司、保健品及農業生技產業、醫療器材與創投等多元領域。旗下轉投資企業包含益安生醫（6499）、順天醫藥生技（6535）、永昕生物醫藥（4726）、金樺生醫（6521）及澳優乳業（港股代號：1717.HK）等10家上櫃及興櫃公司。澳優乳業是大陸首家在港上市的嬰幼兒配方奶粉企業，以嬰兒配方奶、羊奶、有機奶為主要產品。晟德藥業董事長林榮錦表示，2014年投資澳優乳業，主要想透過策略性的投資與併購，串起生技上下游產業鍊的整合。因為生技產業屬高風險投資，澳優乳業能為集團注入穩定而強大現金流，讓資金運用更有彈性、有利於長程規劃，目標成為台灣的生技工業銀行。